StreetInsider.com News Articles

Medicenna to present MDNA11 trial data at SITC 2026 meeting

Mon, 05 Oct 2026 09:00:10 -0400

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF) announced that topline data from its Phase 1/2 ABILITY-1 clinical trial of MDNA11 has been selected for oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, according to a press release from the Toronto and Houston-based company.

The abstract was selected as one of the top 150 abstracts at the meeting. The oral presentation is scheduled for November 7, 2026, from 4:30 to 4:45 p.m. MST during Oral Session 3 at the Phoenix Convention Center in Phoenix, Arizona.

The presentation, designated Abstract Number 517, is titled "MDNA11 Demonstrates Clinical Activity as

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Mon, 05 Oct 2026 09:00:00 -0400

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers

Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

TORONTO and HOUSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract reporting topline data from the Phase 1/2 study of MDNA11 has been selected for

Medicenna Announces Oral Presentation of Topline Data from the Phase 1/2 ABILITY-1 Study of MDNA11 at SITC 2026

Mon, 05 Oct 2026 09:00:00 -0400

The Phase 1/2 ABILITY-1 Clinical Trial is evaluating MDNA11 in expansion cohorts comprised of patients with advanced and metastatic gastrointestinal, endometrial, and melanoma cancers

Selected as one of the Top 150 Abstracts at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Thu, 01 Oct 2026 19:00:00 -0400

TORONTO and HOUSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune diseases, today announced the voting results from the Company’s annual general and special meeting of shareholders held today, October 1, 2026 (the “Meeting”).

Medicenna is pleased to announce that all of the nominees listed in its management information circular dated August 19, 2026 (the “Circular”), were elected as directors. Each director was elected with greater than 97% of the votes cast for by shareholders

Medicenna Announces Results of Annual General and Special Meeting of Shareholders

Thu, 01 Oct 2026 19:00:00 -0400

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Thu, 24 Sep 2026 07:00:00 -0400

TORONTO and HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targeting cancer and autoimmune disease, today announced that an abstract evaluating survival outcomes with bizaxofusp (formerly MDNA55) in unresectable, IDH-wildtype recurrent glioblastoma (rGBM) has been selected for an oral presentation at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO 2026), taking place November 12-15, 2026, in Philadelphia.

The oral presentation will be delivered by Dr. Nicholas A. Butowski, MD, Professor of Neurological Surgery and Director of

Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting

Thu, 24 Sep 2026 07:00:00 -0400

The oral presentation will be delivered by Dr. Nicholas A. Butowski, MD, Professor of Neurological Surgery and Director of

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 07:00:00 -0400

TORONTO and HOUSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune, and inflammatory diseases, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the H.C. Wainwright 28^th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

Details on the presentation are as follows:

Date: Wednesday, September 16^th, 2026
Time: 12:00

Medicenna to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 03 Sep 2026 07:00:00 -0400

Details on the presentation are as follows:

Date: Wednesday, September 16^th, 2026
Time: 12:00

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

Form D Medicenna Therapeutics

Mon, 06 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260706/26736103.html

H.C. Wainwright Reiterates Buy Rating on Medicenna Therapeutics (MDNA)

Thu, 02 Jul 2026 06:44:42 -0400

H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating and $2.50 price target on Medicenna Therapeutics (NASDAQ: MDNA).

The analyst commented: "On June 26, 2026, Medicenna reported FY2026 results (fiscal year ended March 31, 2026) and provided a corporate update. The Phase 1/2 ABILITY-1 study evaluating MDNA11, a long-acting beta-enhanced IL-2 superagonist (no IL-2Rα binding), is on track to complete enrollment in 3Q26, prioritizing select advanced tumor types (cutaneous melanoma, endometrial cancer, and MSI-H/dMMR and MSS/TMB-H cancers) with a focus on 2L/3L post-anti-PD-1 settings. Enrollment is also underway for its Phase 1b NEO-CYT study evaluating MDNA11 in neoadjuvant melanoma with interim

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Fri, 26 Jun 2026 08:45:00 -0400

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors

Enrolment in ABILITY-1 to be completed in Q3 2026 with key data readouts expected in Q4 2026 which will guide development strategy for a potential registrational pathway and partnerships

Enrolment in the NEO-CYT Phase 1b trial, funded by Fondazion Melanoma, is well underway. In this study, which was highlighted at ASCO 2026, MDNA11 is being evaluated in combination with checkpoint inhibitors for

Medicenna raises CDN$4.44 million in public offering of units

Thu, 28 May 2026 09:10:51 -0400

Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.

Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.

Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.

The offering was conducted under a prospectus supplement

Medicenna raises CDN$4.44 million in public offering of units

Thu, 28 May 2026 09:10:51 -0400

Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.

Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.

Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.

The offering was conducted under a prospectus supplement

Medicenna raises CDN$4.44 million in public offering of units

Thu, 28 May 2026 09:10:51 -0400

Medicenna Therapeutics Corp. (TSX: MDNA) completed a public offering of 8,880,000 units at CDN$0.50 per unit, raising approximately CDN$4.44 million in gross proceeds before expenses.

Each unit consists of one common share and one-half of a common share purchase warrant. The warrants allow holders to purchase additional shares at CDN$0.65 each for three years following the closing date.

Bloom Burton Securities Inc. served as the sole agent for the offering under an agency agreement dated May 21, 2026. The company issued 450,100 compensation warrants to the agent, exercisable at CDN$0.50 per share for two years.

The offering was conducted under a prospectus supplement

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Thu, 28 May 2026 09:10:00 -0400

NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES

TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, is pleased to announce the closing of its previously announced marketed public offering of units (the “Units”) of the Company at a price to the public of CDN$0.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately CDN$4.44 million, before deducting Offering expenses and excluding any proceeds